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Hawthorn (Crataegus pinnatiﬁda) is an edible fruit used in traditional Chinese medicine to lower plasma lipids. This study
explored lipid-lowering compounds and underlying mechanisms of action of hawthorn. Hawthorn powder extracts inhibited
acylCoA:cholesterol acyltransferase (ACAT) activity in Caco-2 cells. The inhibitory activity was positively associated with
triterpenic acid (i.e., oleanolic acid (OA) and ursolic acid (UA)) contents in the extracts. Cholesterol lowering eﬀects of hawthorn
and its potential additive eﬀect in combination with plant sterol esters (PSE) were further studied in hamsters. Animals were
fed a semi-synthetic diet containing 0.08% (w/w) cholesterol (control) or the same diet supplemented with (i) 0.37% hawthorn
dichloromethane extract, (ii) 0.24% PSE, (iii) hawthorn dichloromethane extract (0.37%) plus PSE (0.24%) or (iv) OA/UA
mixture (0.01%) for 4 weeks. Compared to the control diet, hawthorn, PSE, hawthorn plus PSE and OA/UA signiﬁcantly lowered
plasma non-HDL (VLDL + LDL) cholesterol concentrations by 8%, 9%, 21% and 6% and decreased hepatic cholesterol ester
content by 9%, 23%, 46% and 22%, respectively. The cholesterol lowering eﬀects of these ingredients were conversely associated
with their capacities in increasing fecal neutral sterol excretion. In conclusion, OA and UA are responsible for the cholesterol
lowering eﬀect of hawthornby inhibiting intestinalACATactivity. Inaddition, hawthornand particularly itsbioactive compounds
(OA and UA) enhanced the cholesterol lowering eﬀect of plant sterols.
1.Introduction
Hawthorn is a berry-like fruit of trees from the species
of Crataegus, which has been documented as a food in
China as early as the seventh millennium before Christ
[1]. Hawthorn is also one of the commonly used remedies
in traditional Chinese medicine (TCM). The history and
traditional uses of (10g/day) dry hawthorn in TCM is to
relieve fullness that follows overeating or consumption of a
fatty meal. During the last decades hawthorn has received
much attention because of its potential to reduce plasma
cholesterol and triacylglycerol (TAG) concentrations [2–
9] and to treat heart arrhythmia [10–12]. However, the
scientiﬁc evidence of these beneﬁcial eﬀects of hawthorn still
needs to be further substantiated, including identiﬁcation of
its bioactive compounds and the underlying mechanisms of
action.
There are diﬀerent species of Crataegus. In China,
Crataegus pinnatiﬁda is predominantly used as TCM rem-
edy [2, 6, 8], while C. monogyna and C. oxyacantha are
commonly used in Europe for the treatment of heart
failure [10, 11]. Recently, Zhang et al. [3] reported that
an aqueous ethanolic extract of hawthorn (C. pinnatiﬁda)
could inhibit intestinal acylCoA:cholesterol acyltransferase
(ACAT) activity in hamsters. However, bioactive compounds
responsible for the inhibition of ACAT in the hawthorn
extract have not yet been identiﬁed. Hawthorn is rich in
triterpenic acids (e.g., oleanolic acid (OA) and ursolic acid
(UA)) and polyphenols (e.g., epicatechin, procyanidin B2,
procyanidin B5, procyanidin C1, hyperoside, isoquercitrin
and chlorogenic acid) [13]. In the present study, we aimed
to identify ACAT inhibiting compounds in hawthorn. Initial
tests in Caco-2 cells, a human intestinal cell line, have
shown that OA and UA are the bioactive compounds
present in hawthorn that inhibit ACAT activity. To further
conﬁrm these in vitro ﬁndings, we conducted a study in
hamsters to investigate the cholesterol lowering eﬀect of
a hawthorn extract and a mixture of OA/UA resembling
their concentrations found in hawthorn. Since hawthorn
would exert its cholesterol lowering eﬀect via a mechanism
diﬀerent from that of plant sterols [14], we further explored
in this study whether the combination of plant sterols esters2 Evidence-Based Complementary and Alternative Medicine
and hawthorn extract would have an additive cholesterol
lowering eﬀect.
2.MaterialsandMethods
Caco-2 cells were obtained from the ATCC (American Type
Culture Collection), Rockville, MD, USA. RPMI 1640 and
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM), penicillin,
streptomycin and fetal calf serum (FCS) were purchased
from Gibco, Life Technologies Ltd, Paisley, UK. Cell cul-
ture plates and ﬂasks were supplied by Corning, Cam-
bridge, MA, USA. Dl-Mevalonic acid lactone was acquired
from Fluka, Buchs, Switzerland. [9,10-3H]oleic acid and
[4-14C]cholesteryl-oleate were purchased from Amersham,
Buckinghamshire, UK. Oleic acid, silicic acid, OA and UA
were purchased from Sigma-Aldrich, Zwijndrecht, NL. All
organic solutions were obtained from Merck, Amsterdam,
NL. One batch of dried hawthorn (C. pinnatiﬁda)f r u i tw a s
obtained from a TCM pharmacy, Rotterdam, NL. Other
chemicals were obtained in their commercially available
highest purity grade.
2.1. Preparation of Hawthorn Extracts. Dried hawthorn fruit
was milled to a powder using a grinder. The same batch
was used for the in vitro experiments and the animal
study. For the in vitro experiments 20g of dry hawthorn
fruit powder was extracted with 100mL dichloromethane,
ethylacetate, acetone, ethanol or heptane, respectively, at
roomtemperaturefor1.5h.Theobtainedextractsweredried
under nitrogen ﬂow. The yield of these extractions and their
OA and UA contents are presented in Table 1.
For the animal study, 425g of dried hawthorn fruit
powder was extracted ﬁrst with ethanol (2L) for 12h at
80◦C using a Soxhlet extractor. The ethanol extract was
then dried using a vacuum rotary evaporator to obtain
a raw ethanol extract. This raw extract was subsequently
extracted manually with 1L dichloromethane under room
temperature and the generated extract was dried in order to
obtain the hawthorn dichloromethane extract.
2.2. Analysis and Quantiﬁcation of OA and UA in Hawthorn
Extracts. Thecompositionofthehawthornextractswasana-
lyzed using reversed-phase high-performance liquid chro-
matography (HPLC). The HPLC was carried out on a HP
1090 instrument (Agilent Technologies, Wilmington, DE,
USA) equipped with a Supelcosil LC-18-T column (15 cm
× 4.6mm i.d., Supelco, Bellefonte, PA, USA). The hawthorn
extracts (100mg) were dissolved in DMSO (1mL) and 10μL
of the solutions were injected onto the column. The mobile
phase was a mixture of 15% H2O, 85% methanol and
0.15% acetic acid (v/v) with a ﬂow rate of 1mL/min. The
eﬄuent was monitored using a UV detector at 210nm.
Identiﬁcation of OA and UA peaks was based on retention
time as comparing with those of pure OA and UA (external
standards) under the same conditions.
Further identiﬁcation and quantiﬁcation of OA and
UA in the hawthorn dichloromethane extract used for the
animal study was conducted by using gas chromatography
mass spectrometry (GC–MS). GC–MS analysis was per-
formed using an Agilent 6890 Series GC and Micro Mass
GCT (Time of Flight Mass Spectrometer, JAS, Eindhoven,
NL). The GC analysis was performed with a DB-5MS
15 m × 0.25mm (d = 0.1μm) column (JAS, Eindhoven,
NL). OA/UA containing samples (after derivatization with
N,O-bis(trimethylsilyl)triﬂuoroacetamide(BSTFA)weredis-
solved in hexane (∼25–30 ng/μL). The ﬂow rate of helium as
mobile phase was 1.0mL/min. Oven temperature program
was 1min at 60◦C and then the temperature increased
to 310◦C (increase 10◦C/min) and from 310◦C to 325◦C
(increase 20◦C/min) and maintained at 325◦C for 25.3 min.
Mass spectra were acquired in EI mode using interface
temperature of 325◦C. The mass spectrometer was operated
in positive mode at 70eV. The scanning range was m/z 29–
650. For quantiﬁcation of UA, ions 203.1970, 482.4397 and
585.4684 were used. For quantiﬁcation of OA, ions 203.1961,
482.4407 and 585.4701 were used.
2.3. In Vitro Study
2.3.1. Cell Culture. Caco-2 cells were routinely cultured in
75cm2 culture ﬂasks with DMEM supplemented with 20%
(v/v) FCS, 10 IU/ml penicillin and 10μg/mL streptomycin
(culture medium). Cells were incubated at 37◦C, 5% CO2.
The medium was refreshed every 2-3 days. Once the cells
were conﬂuent, they were passaged with a split ratio of
1:4. In experiments, cells were seeded to 24-well plates
and cultured for 6 days before they were exposed to the
test compounds or extracts. Individual test compounds and
extracts were dissolved in dimethylsulfoxide (DMSO). Cor-
responding amounts of these DMSO solutions (about 50μg
each extract per 10μL DMSO) were added to cell culture
media (1mL) to have ﬁnal concentrations as indicated (see
Results section, Table 2). Medium DMSO concentration was
the same for all treatments and did not exceed 1% (v/v).
DMSO concentration up to at least 2% in the medium had
no eﬀect on ACAT activity (data not shown). Cells were
culturedintheseconditionedmediafor24h.Viabilityofcells
was assessed with an ATP assay by using the ViaLight Plus kit
LT07-121 (Lonza, Bath, UK) as described previously [15].
2.3.2. ACAT Activity in Caco-2 Cells. Four hours before
the end of the overnight cellular incubation with the test
compounds or extracts, [9,10-3H]oleic acid dissolved in
DMEM containing fatty acid-free human serum albumin
was added to each well (1μCi/well, 62.5μM ﬁnal concen-
tration in medium) to monitor synthesis of cholesterol
esters. Incubation was ended by transferring the cell culture
plates on ice and then the medium was removed. The cells
were washed twice with ice-cold phosphate-buﬀered saline
(PBS) and the lipids were extracted twice with isopropyl
alcohol:heptane(4:1v/v).Thelipidextractwasdriedunder
nitrogen ﬂow. The sample was then dissolved in 0.5mL
hexane:ethyl acetate (49:1 v/v). The cholesterol esters were
isolated from the extracted lipids using a silica column
(prepared in a Pasteur’s pipette ﬁlled with silica) which was
eluted four times with 1mL elution solvent as described byEvidence-Based Complementary and Alternative Medicine 3
Table 1: OA and UA concentrations in the dried hawthorn fruit powder and extracts.
Extraction solvents Hawthorn
powder (g)
Dry extract
yield (g)
OA and UA in dry extracts (g/100g)
Calculated OA + UA in
hawthorn powder
(g/100g)
OA UA OA + UA
I II III (II × III)/I
Heptane 20a 0.044 1.0 1.6 2.6 0.01
Ethanol 20 0.986 1.5 6.2 7.7 0.38
Aceton 20 0.260 5.4 20.3 25.7 0.33
Ethylacetate 20 0.149 8.1 30.8 38.9 0.29
Dichloromethane 20 0.118 9.0 31.5 40.5 0.24
Dichloromethane 425b 38.25 0.4 2.6 3.0 0.27
aFor the in vitro experiments, 20g of dried hawthorn powder was extracted with 100mL dichloromethane, ethylacetate, acetone, ethanol or heptane,
respectively, at room temperature for 1.5h. The obtained extracts were then dried under nitrogen ﬂow.
bFor the animal study, 425g dried hawthorn fruit powder was extracted with ethanol followed by dichloromethane (details are described in Section 2).
Triterpenic acid concentrations in the extracts were measured by HPLC and data are presented as mean value of two measurements.
Table 2: ACAT inhibitory eﬀect of hawthorn extracts and pure OA and UA in Caco-2 cells.
Test materials Final OA + UA content in medium (μM) ACAT activity (percentage of control)
Control 0 100 ± 0.0
Solvent extract (50μg/well)
Heptane 2.8 77.2 ± 11.8
Ethanol 8.4 86.4 ± 10.8
Acetone 28.1 46.7 ± 8.6
Ethylacetate 42.6 36.5 ± 8.0
Dichloromethane 44.3 37.9 ± 11.1
Pure compounds
OA 50.0 30.9 ± 3.9
UA 50.0 50.5 ± 8.5
Hawthorn powder was extracted with indicated solvents to generate various hawthorn extracts. Caco-2 cells were incubated with medium (1mL) containing
50μgofeachhawthornextractdissolvedin10 μLDMSOorindicatedamountofOAorOAfor24h.OAandUAcontentineachextractispresentedinTable1.
4h before the end of the incubation, [9,10-3H]oleic acid (62.5μM, 1 μCi/well) was added to each well to monitor cholesterol ester synthesis. Cellular lipids
were extracted by solvents and cholesterol esters were isolated using a silica column as described in Methods. The radioactivity of generated [3H]cholesterol
esters was measured by scintillation counting. Data are presented as mean ± SE from six independent incubations. ACAT activity in each treatment was
signiﬁcantly diﬀerent from control value (P < .05).
Chautan et al. [16]. The radioactivity of the [3H]-labelled
cholesterol esters was counted by using a liquid scintillation
counter (Packard Tri-Carb Model 1900CA, Downers Grove,
USA) after adding 7mL scintillation cocktail.
2.4. Animal Study. This animal study was conducted at the
Erasmus Animal Experimental Center, Erasmus University,
Rotterdam, NL. The study process was in conformity with
the National Research Council Guide for the Care and Use
of Laboratory Animals and Public Health Service Policy on
Human Care and Use of Laboratory Animals. The study
protocol was approved by the ethical committee of Erasmus
U n i v e r s i t y ,R o t t e r d a m ,N L .
2.4.1. Animals. Male Lakeview Golden (LVG) Syrian ham-
sters (Mesocricetus auratus) with a body weight of approxi-
mately 75g were obtained from Charles River Laboratories,
Inc., Wilmington, MA, USA. After 1 week of acclimatization,
hamsters were randomly allocated to ﬁve groups of 20
animals each, based on their body weight. The hamsters
were individually housed in Macrolon II cages with a layer
of sawdust as bedding. Animals were kept in an environ-
mentallycontrolledroom(temperature22–25◦Candrelativ e
humidity ∼55%) with a 12h light–dark rhythm (lights oﬀ
6:00–18:00h). Throughout the study, the animals had free
access to food and drinking water. Clinical observations were
routinely done and 24h food consumption and body weight
gain were measured weekly during the experimental period.
2.4.2. Test Compounds. In the in vitro tests, the dichlo-
romethane extract of hawthorn was shown to have the
strongest ACAT-inhibitory activity amongst the extracts
tested (Table 2). Therefore, the dichloromethane extract
(carried out in large scale) was used in the hamster study.
The dichloromethane extract contained 0.4% OA and 2.6%
UA as measured by HPLC. Plant sterol esters (PSE) were
prepared by esterifying soy plant sterols with fatty acids
from sunﬂower oil (esteriﬁcation degree of >92%) (Unilever4 Evidence-Based Complementary and Alternative Medicine
Table 3: Composition of the control and treatment diets.
Ingredients (g/kg diet) Diets
Control Hawthorn PSE Hawthorn + PSE OA + UA
Calcium caseinate 161.4 161.4 161.4 161.4 161.4
Plant sterol esters (PSE) — — 2.4 2.4 —
Dichloromethane extract of hawthorn — 3.7 — 3.7 —
Oleanolic acid (OA) — — — — 0.015
Ursolic acid (UA) — — — — 0.095
Vitamin mix 11.3 11.3 11.3 11.3 11.3
Mineral mix 39.7 39.7 39.7 39.7 39.7
Arbocel (ﬁbres) 56.7 56.7 56.7 56.7 56.7
Fat 126.1 126.1 126.1 126.1 126.1
l-Cysteine hydrochloride 2.1 2.1 2.1 2.1 2.1
Choline bitartrate 2.8 2.8 2.8 2.8 2.8
Cholesterol 0.8 0.8 0.8 0.8 0.8
Maize starch 599.1 595.4 596.7 592.9 599.0
Research and Development, Vlaardingen, NL). The soy plant
sterol composition was beta-sitosterol 46.7%, beta-sitostanol
1%, campesterol 26.9%, stigmasterol 18.3%, brassicasterol
2.7% and other plant sterols 4.4%.
2.4.3. Diets. During the acclimating period, hamsters were
fed a semi-puriﬁed diet based on the AIN-93 rodent diet
[17]. During the experimental period, hamsters were fed
ﬁve diﬀerent experimental diets for 4 weeks. Fat con-
tributed to 30% of the total dietary energy and saturated
fatty acids, monounsaturated fatty acids and polyunsatu-
rated fatty acids contributed 16.8%, 8.5% and 4.7% of
total dietary energy, respectively. The composition of the
dietary fat resembled that of a typical Western diet. The
experimental diets contained 0.08% (w/w) cholesterol. The
composition of the mineral mix and the vitamin mix were
described previously [18]. The detailed compositions of
the experimental diets are shown in Table 3. These diets
were designed to be identical in composition, except for
the testing compounds. In order to ensure homogenous
mixture of diets, cholesterol and PSE were incorporated
into the fat blend and OA/UA were pre-mixed with a small
amount of starch before they were mixed with other diet
components.
2.4.4. Sample Collection. In week 3, fecal samples were
collected and weighted over two consecutive days. The feces
were lyophilized and dry-weight of the fecal samples was
recorded. Aliquots of homogenized fecal samples were used
for measurements of fecal neutral sterols and bile acid
excretion. At the end of the study, hamsters were fasted
overnight (∼16h). Blood samples were drawn into EDTA-
wetted syringes by aorta puncture under halothane narcosis.
The animals were killed by decapitation, and liver and
intestinal samples were collected as described below. Plasma
was collected after centrifugation at 1500 × ga tr o o m
temperature for 10 min.
2.4.5. Liver Sample Collection. The liver was excised, ﬂushed
with PBS and liver weight was measured. About 1g of liver
tissue was sampled and frozen at −20
◦C for hepatic lipid
analysis.
2.4.6. Plasma Lipid and Lipoprotein Analysis. Plasma total
cholesterol (TC) and TAG concentrations were determined
enzymatically by using commercial assay kits (CHOD-PAP
and GPO-PAP method, Roche Diagnostics, Basel, CH)
and carried out on a COBAS Mira S automated ana-
lyzer (Roche Diagnostics, Basel, CH). Lipoprotein fractions
were isolated from 0.6mL plasma by sequential density-
ultracentrifugation [19]. Three fractions were isolated based
on the following densities: VLDL (d < 1.006kg/L), LDL
(1.006 < d < 1.055kg/L), HDL (1.055 < d < 1.21kg/L). TC
and TAG concentrations in the lipoprotein fractions were
determined as described above.
2.4.7. Hepatic Cholesterol Analysis. A 300mg portion of
liver tissue was homogenized. Lipids in liver samples were
extracted according to a modiﬁed method described by
Bligh and Dyer [20], in which chloroform was substituted
by dichloromethane. TC and TAG were determined as
described above. Free cholesterol (FC) was measured using
a commercial kit supplied by WAKO (Richmond, VA, USA).
The concentration of cholesterol esters was calculated as the
diﬀerence between TC and FC.
2.4.8. Fecal Bile Acid and Neutral Sterol Measurements. Fecal
bile acid concentrations were measured by GC and fecal
neutralsterolconcentrationsweremeasuredbyGC–MS.The
detailed procedures of these two assays have been described
previously [21].
2.4.9. Data Presentation and Statistical Analysis. All results
are expressed as mean and standard error (SE). A two-
way analysis of variance (ANOVA) (two-by-two table) wasEvidence-Based Complementary and Alternative Medicine 5
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Figure 1:HPLCproﬁleofthetriterpenicacidsinthedichlorometh-
ane extract of the dried hawthorn fruit powder is depicted. Dried
hawthorn fruit powder was extracted sequentially with ethanol by
using Soxhlet extractor at 80◦C, followed by a dichloromethane
extraction of the dried ethanol extract. Signal detection was carried
out at 210nm. Peak numbers: 1, (unknown); 2, OA; 3, UA; and 4,
(unknown).
applied for determining the main eﬀect of the hawthorn
extract (i.e., hawthorn group plus hawthorn + PSE group
compared with control group plus PSE group) and of
the main eﬀect PSE (i.e., PSE group plus hawthorn +
PSE compared with control group plus hawthorn group).
Statistical diﬀerences between the individual groups were
calculated using a Dunnett multiple comparison test. The
statistical analysis was conducted by using software SAS
(version 9.1). Diﬀerences were considered signiﬁcant at
P < .05.
3. Results
3.1. Triterpenic Acid Content in Dried Hawthorn Fruit Powder
and Hawthorn Extracts. A typical HPLC proﬁle of the
triterpenic acids in the dichloromethane extract is shown in
Figure 1. The triterpenic acid proﬁle is comparable to that
reported by others [13]. As shown in Table 1, heptane had
only a limited capacity to extract triterpenic acids from the
hawthorn powder. In contrast, dichloromethane extraction
as compared to other tested solvents generated a higher
purity (40.5%, w/w) of the triterpenic acids OA and UA
in the extract. By using these solvents (except heptane) for
extraction, it was calculated that the dried hawthorn fruit
powder contained 0.24–0.38% (w/w) triterpenic acids (OA
+ UA). It was reported that fresh hawthorn (C. pinnatiﬁda)
fruit obtained from 37 cultivators contained 0.07–0.14%
(average 0.11%) OA + UA [13].
For the animal study, dried hawthorn fruit powder was
extracted with ethanol and was subsequently extracted with
dichloromethane. Increasing the extraction temperature
could increase the yield of dichloromethane extracted mass
(9g per 100g hawthorn powder), while the triterpenic acid
concentration in this extract was signiﬁcantly decreased
(3%). The calculated triterpenic acid concentration in the
dried hawthorn powder, based on the extraction yield and
OA + UA concentration in the dichloromethane extract,
was 0.27%, which is in agreement with that (0.24%) in the
extractcarriedoutunder roomtemperature(seeabove).The
majorityoftheremaindersinthehawthorndichloromethane
extract were mono-, and disaccharides based on GC–MS
results (data not shown).
3.2. Study in Cultured Caco-2 Cells
3.2.1. Validation of the In Vitro Test System. Cell viability
was not inﬂuenced by any of the described incubations as
indicated by the ATP assay (data not shown). Mevalonic
acid (10mM) increased isotope-labeled cholesteryl oleate
production by up to 60%. An ACAT inhibitor (F-1394)
inhibited ACAT activity by about 50% at a dose of 0.1μM.
These data indicated that Caco-2 cells did respond to various
stimuli by modulating cholesteryl ester (CE) production.
3.2.2. Eﬀect of Hawthorn Extracts on ACAT Activity (Table 2).
Caco-2 cells were incubated with increasing amounts of
the hawthorn ethanol extract (10–300μg/mLmedium per
well) for 24h. The incorporation of [9,10-3H]oleic acid into
cholesterol esters was dose-dependently inhibited (data not
shown). To explore the potential bioactive compounds in
hawthorn, extractions by using dichloromethane, ethylac-
etate, acetone, ethanol and heptane as solvents were made
and the ACAT inhibitory eﬀects of these extracts were tested
in Caco-2 cells. The dichloromethane extract showed the
strongest ACAT activity inhibitory eﬀect amongst all tested
extracts (Table 2). Via HPLC-analysis it was revealed that
the contents in OA and UA were signiﬁcantly diﬀerent
among these extracts, while the ratio of OA/UA was con-
sistently 1:6 in all extracts. The ACAT inhibitory activity
of these extracts was strongly associated with their OA
and UA contents. To further conﬁrm whether OA and
UA are bioactive compounds, ACAT inhibitory eﬀects of
pure OA and UA were tested. Both OA and UA inhibited
ACAT activity. The potency of the inhibitory eﬀect of
OA and UA was similar to that found for the extracts
based on an equal amount of OA/UA. These in vitro data
strongly suggested that OA and UA are responsible for
the ACAT inhibitory eﬀect of hawthorn. Compared to OA,
UA had a slightly lower inhibitory activity. OA and UA
had no eﬀects on cell uptake of either [14C]cholesterol or
[9,10-3H]oleic acid from the medium (data not shown),
indicating that the inhibitory eﬀect is via speciﬁcally
inhibiting ACAT activity but not via inhibiting transport
of precursors of cholesterol esters, that is, FC or fatty
acids.
3.3. Hamster Study
3.3.1. Food Intake and Body Weight Gain. Hamsters fed the
diﬀerent diets showed no signiﬁcant diﬀerences in food
intake (range 7–8.5g/day for all animals) and body weight
gain (5–5.5g/week) during the 28-day treatment period.6 Evidence-Based Complementary and Alternative Medicine
Table 4: Plasma and lipoprotein lipid concentrations (mmol/L) of hamsters fed the control and treatment diets.
Plasma lipids Diets
Control Hawthorn PSE Hawthorn + PSE OA + UA
TC 5.85 ± 0.21 5.84 ± 0.19 (0%) 5.56 ± 0.19 (−5%) 4.93 ± 0.19 (−16%)∗ 5.39 ± 0.18 (−8%)
Non-HDL-C 2.08 ± 0.12 1.92 ± 0.10 (−8%)∗ 1.90 ± 0.08 (−9%)∗ 1.64 ± 0.10 (−21%)∗ 1.96 ± 0.08 (−6%)
HDL-C 3.51 ± 0.14 3.53 ± 0.14 (+1%) 3.40 ± 0.14 (−3%) 3.18 ± 0.12 (−9%) 3.27 ± 0.15 (−7%)
TAG 3.79 ± 0.40 3.56 ± 0.40 (−6%) 3.45 ± 0.35 (−9%) 3.19 ± 0.23 (−16%) 3.37 ± 0.36 (−11%)
Hamsters were fed diets as indicated in Table 3 for 4 weeks. At the end of the study, fasting (16h) blood samples were collected and plasma total cholesterol
(TC) and triacylglycerol (TAG) concentrations were determined enzymatically. Plasma lipoproteins (VLDL, LDL and HDL) were fractionated by density-
ultracentrifugation. Cholesterol (-C) concentrations in HDL and non-HDL (VLDL + LDL) were measured enzymatically. Data are presented as means ± SE
(n = 20 animals per group). Data in parentheses represent percentage diﬀerence compared to control group. Asterisk indicates that the value is signiﬁcantly
diﬀerent from that of control (P < .05).
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Figure 2: Hepatic FC and CE concentrations of hamsters fed the
control and treatment diets for 4 weeks. A 300mg portion of liver
tissue from each animal was homogenized. Lipids were extracted
using the method described by Bligh and Dyer and total cholesterol
and FC were measured enzymatically. Concentration of CE was
calculated as the diﬀerence between total cholesterol and FC. Data
are presented as mean ± SE (n = 20 animals per group). ∗P < .01 as
compared to control.
3.3.2. Plasma Lipids and Lipoproteins (Table 4). Plasma
VLDL and LDL fractions were combined as non-HDL.
Hamsters administered hawthorn, PSE or hawthorn plus
PSE had signiﬁcantly lower plasma non-HDL cholesterol
(non-HDL-C) concentrations than hamsters of the control
group (P < .05). Only the hawthorn plus PSE diet lowered
plasma TC as compared to control (P < .05). HDL-C and
TAG concentrations were similar among all the ﬁve groups.
OA/UA lowered plasma TC and non-HDL-C to an extent
similartothatofhawthorn.However,thiseﬀectdidnotreach
statistical signiﬁcance (P < .30).
3.3.3. Liver Weight and Hepatic Lipid Concentrations (Fig-
ure 2). At the end of the study, absolute (range 4.2–4.4g)
and relative liver weights (range 3.5–3.6% of body weight)
didnotdiﬀerbetweenthegroups.HepaticFCconcentrations
were not signiﬁcantly diﬀerent between the groups (P =
.24). However, hawthorn extract, PSE and OA/UA lowered
hepatic concentration of cholesterol esters by 9% (P = .06),
23% (P < .01) and 22% (P = .05), respectively (Figure 2).
The combination of hawthorn extract plus PSE resulted in
the strongest decrease (46%) in hepatic cholesterol esters
(P < .01).
3.3.4. Fecal Excretion of Neutral Sterols and Bile Acids
(Table 5). Hawthorn extract, PSE or OA/UA did not change
daily fecal dry weight. Fecal output of neutral sterols was
signiﬁcantly increased in hamsters fed the hawthorn extract
orOA/UAcomparedtothecontroldiet.ThePSEdietslightly
(3%) increased fecal neutral sterol excretion but this did
not reach statistical signiﬁcance (P > .05). Diets containing
hawthorn or OA/UA signiﬁcantly decreased fecal output of
total bile acids (P < .05).
The two PSE-containing diets (PSE and hawthorn plus
PSE) signiﬁcantly increased fecal plant sterol excretion by
7.5-fold (P < .01) while with hawthorn and OA/UA added
to the diets the fecal plant sterol excretion was not diﬀerent
as compared to the control diet.
4. Discussion
This study investigated the eﬀect of hawthorn on cholesterol
metabolism in hamsters and in human Caco-2 cells. The
dichloromethane hawthorn extract lowered plasma non-
HDL-C by 8% without changing HDL-C. This ﬁnding is
further supported by the fact that the hawthorn extract also
reduced hepatic total cholesterol and CE contents. Hepatic
cholesterol esters are the storage form of cholesterol in the
liver. In rodents such as mice [22] and hamsters [21], hepatic
CE concentration is more sensitive than plasma cholesterol
in reﬂecting to the cholesterol lowering eﬀect of dietary
ingredients. Besides in hamsters, hawthorn (in the form
of extracts) has been reported to lower plasma cholesterol
concentration in rats [4, 5] and rabbits [2]. These results,
taken together, provide scientiﬁc evidence that hawthorn
could be a useful natural ingredient for lowering plasma
cholesterol concentrations in humans [6–8]. Furthermore,
our study showed that the combination of hawthorn extract
with PSE had an additive cholesterol lowering eﬀect.
Hawthorn is rich in triterpenic acids (OA and UA) and
polyphenols (e.g., epicatechin, procyanidin B2, procyanidin
B5, procyanidin C1, hyperoside, isoquercitrin and chloro-
genic acid) [13]. The present study demonstrated that in
particular OA and UA are responsible for the cholesterolEvidence-Based Complementary and Alternative Medicine 7
Table 5: Fecal output and fecal excretion of plant sterols, neutral sterols and bile acids in hamsters fed the control and treatment diets.
Fecal
Diets
Control Hawthorn PSE Hawthorn + PSE OA + UA
Fecal output (g/day)
Dry weight 0.63 ± 0.03 0.62 ± 0.03 0.57 ± 0.03 0.61 ± 0.03 0.63 ± 0.02
Fecal excretion of sterols and bile acids (μmol/day)
Plant sterols 2.19 ± 0.07 2.63 ± 0.17
(+20%)
16.35 ± 1.13
(+647%)∗∗
17.86 ± 1.09
(+716%)∗∗ 2.40 ± 0.10 (+9%)
Neutral sterols 9.90 ± 0.43 11.54 ± 0.54
(+17%)∗
10.24 ± 0.57
(+3%)
11.58 ± 0.78
(+17%)∗
12.14 ± 0.46
(+23%)∗
Bile acids 1.68 ± 0.13 1.42 ± 0.14
(−15%)∗
1.64 ± 0.16
(−2%)
1.31 ± 0.10
(−22%)∗ 1.30 ± 0.11 (−23%)∗
Neutral sterols +
Bile acids 11.71 ± 0.47 13.04 ± 0.61
(+11%)
11.97 ± 0.66
(+2%)
12.85 ± 0.76
(+10%) 13.47 ± 0.49 (+15%)
PSE: plant sterol esters. Forty-eight hours fecal samples were collected in Week 3. Plant sterols include campesterol, campestanol, stigmasterol, stigmastanol,
beta-sitosterol, sitostanol and brassicasterol. Neutral sterols include cholesterol, cholestanol and coprostanone. Values are means ± SEM (n = 20 animals per
group). Data in parenthesis represent percentage diﬀerence compared to control group.
∗P < .05; ∗∗P < .01.
loweringeﬀectofhawthorn.Thisconceptisbasedonthefact
thatthemixtureofOAandUA,whichresembledtheamount
of these compounds in the hawthorn extract, exerted eﬀects
toasimilarmagnitudeasobservedwiththehawthornextract
both in vitro and in vivo. These eﬀects include (i) inhibition
of ACAT activity (in vitro) ,( i i )ad e c r e a s eo fp l a s m aa n d
liver cholesterol concentrations to a similar extent, (iii) an
increase in fecal neutral sterol excretion and (iv) a reduction
offecalbileacidexcretion.Althoughwedidnottesttheeﬀect
of hawthorn polyphenols on their ACAT inhibitory activity
in this study, we have found in our vitro experiments that
other natural compounds such as ﬂavonoids, for example,
hesperetin, genistein, or ﬂavanolignan (e.g., silymarin) and
sterolsdidnot inhibit ACATactivityinCaco-2 cells(datanot
shown).
Several lines of evidence show that OA and UA lower
plasma cholesterol via inhibiting ACAT activity. First, our
cellular experiments showed that the ACAT inhibitory eﬀect
of the hawthorn extracts correlates with the triterpenic
acid (OA plus UA) content in the extracts. Secondly, the
pure OA and UA exerted their ACAT inhibitory eﬀect
in Caco-2 cells to an extent similar to that of hawthorn
extracts containing equal amounts of OA and UA. Thirdly,
both the hawthorn extract and OA/UA mix increased fecal
neutral sterols excretion in hamsters, indicating decreased
intestinal cholesterol absorption. Compared to PSE (0.24%
of diet, w/w), a much lower dose of OA/UA (0.01% of
diet, in pure form or derived from hawthorn extract)
caused a similar cholesterol lowering eﬀect. These results
suggest that the cholesterol lowering mechanism by which
hawthorn and OA/UA lower plasma cholesterol is diﬀerent
from that of PSE. PSE lower plasma cholesterol via partly
inhibiting intestinal cholesterol absorption, primarily via
competing with cholesterol for incorporation into dietary
mixed micelles [14]. Therefore a relatively large amount
of PSE (0.24% of diet, which is more than the dietary
cholesterol content (0.08%) in this study) is needed to
competitively inhibit cholesterol absorption. For OA/UA,
which inhibits cholesterol absorption at a low dose (0.01%),
a plausible explanation would be that OA/UA reduced
cholesterol absorption via primary inhibition of intestinal
ACATactivity.Ourﬁndingsarefurthersupportedbyarecent
study performed by Lee et al. [23] in which both OA and UA
isolated from the leaves of Lycopus lucidus inhibited ACAT
activity in Hi5 cells transfected with human ACAT genes.
Intestinal ACAT plays an important role in the absorption of
cholesterol. In enterocytes, absorbed cholesterol is esteriﬁed
byACATtoformcholesterolesters,whichserveaspartofthe
core lipid for chylomicron assembly. Several synthetic ACAT
inhibitors have been shown to lower plasma cholesterol in
animals [24, 25].
Hawthorn and OA/UA lowered hepatic CE concentra-
tions. This CE lowering eﬀect of hawthorn may not be
attributed to inhibiting ACAT activity in the liver because
both PSE and hawthorn had similar eﬀects on hepatic
CE concentration. It has been established that PSE are
poorly absorbed from gut lumen and do not modulate
hepatic ACAT activity [22]. Thus, the remarkable decrease
in hepatic cholesterol esters with both hawthorn and PSE is
more likely the result of their plasma cholesterol lowering
eﬀect via reducing cholesterol absorption. Therefore, the
d e c r e a s e da m o u n to fh e p a t i cc h o l e s t e r o le s t e r si sas e c o n d a ry
(consequential) eﬀect rather than a primary eﬀect. Further
supporting this concept is the fact that hepatic FC concen-
tration was not increased by the treatment of hawthorn or
OA/UA.Moreover,asyntheticACATinhibitor(YIC-C8-434)
was also shown to lower plasma cholesterol concentration
in rats via inhibiting intestinal, but not hepatic ACAT
activity [26]. Hawthorn and OA/UA slightly, but statistically
signiﬁcantly, lowered fecal bile acid output in hamsters. In
contrast to these results, Zhang et al. [2, 3] demonstrated
that hawthorn could enhance fecal bile acid excretion by up-
regulationofhepaticcholesterol7-alpha-hydroxylaseactivity
in hamsters [3] and rabbits [2]. Since cholesterol is the
precursor of bile acids, it can not be excluded that the
decreased fecal bile acid excretion by hawthorn or OA/UA8 Evidence-Based Complementary and Alternative Medicine
in this study is a consequence of the hepatic cholesterol
loweringeﬀectoftheseingredients.Alternatively,Zhangetal.
usedanethanolextractofhawthorn[3]orhawthornpowder
[2] while in this study we used a dichloromethane extract
of dried hawthorn fruit powder. Based on our ﬁndings, the
purity of the triterpenic acids in the dichloromethane extract
was higher than that in ethanol extract (Table 1). Possibly,
other ingredients in the ethanol extracts or in the hawthorn
powder used by Zhang et al. [2, 3] may have increased fecal
bile acid excretion. Further studies are warranted to fully
understand the eﬀect of hawthorn and OA/UA on hepatic
bile acid metabolism.
There are two types of ACAT, that is, ACAT1 and ACAT2,
in the body [27]. The ACAT1 gene is expressed in almost all
tissues [27]. ACAT1 is not involved in lipoprotein formation.
A selective ACAT1 inhibitor (K604) showed no cholesterol
lowering eﬀect [28]. Similarly, knockout of the ACAT1 gene
did not lower plasma cholesterol concentrations in mice but
rather increased plasma cholesterol [29]. In contrast, ACAT2
is expressed only in hepatocytes and enterocytes and its
main function is to provide cholesterol esters for transport
in lipoproteins [27]. ACAT2-knockout mice, compared to
wild-type mice, absorbed less cholesterol [30] and they were
resistant to diet-induced hypercholesterolemia [31]. In this
context, the cholesterol lowering eﬀect of hawthorn and
OA/UA seems more likely a result of inhibiting intestinal
ACAT2 activity.
In conclusion, the present hamster study shows that
hawthorn exerts a cholesterol lowering eﬀect via a mech-
anism which is diﬀerent from that of PSE. Hawthorn and
PSE had an additive eﬀect on lowering plasma cholesterol
concentrations and could therefore oﬀer a promising com-
bination for further cholesterol-lowering by dietary means.
OA and UA are the bioactive compounds responsible for
the beneﬁcial eﬀects of hawthorn, which reduce intestinal
cholesterol absorption via inhibition of the intestinal ACAT
activity.
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